NGVTIngevity Corp

NYSE ingevity.com


$ 53.60 $ -1.24 (-2.26 %)    

Friday, 03-May-2024 15:59:55 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 53.56
$ 55.34
$ 0.00 x 0
$ 0.00 x 0
$ 53.23 - $ 56.19
$ 36.66 - $ 68.11
374,454
na
1.95B
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 10-28-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-19-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-20-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-28-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 03-02-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-17-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-ingevity-raises-price-target-to-58

Oppenheimer analyst Ian Zaffino maintains Ingevity (NYSE:NGVT) with a Outperform and raises the price target from $50 to $58.

 ingevity-q1-2024-adj-eps-052-beats-032-estimate-sales-340100m-beat-318960m-estimate

Ingevity (NYSE:NGVT) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.32 by 62.5 ...

 jefferies-upgrades-ingevity-to-buy-raises-price-target-to-62

Jefferies analyst Daniel Rizzo upgrades Ingevity (NYSE:NGVT) from Hold to Buy and raises the price target from $52 to $62.

 ingevity-q4-2023-adj-eps-021-beats-019-estimate-sales-37170m-beat-33230m-estimate

Ingevity (NYSE:NGVT) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.19) by 210...

 recap-ingevity-q4-earnings
Recap: Ingevity Q4 Earnings
02/21/2024 21:25:35

 earnings-scheduled-for-february-21-2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on...

 ingevitys-earnings-outlook
Ingevity's Earnings Outlook
02/20/2024 14:01:51

 zk-international-meets-nasdaq-standards-overbought-trends-in-materials-sector-galiano-gold-updates-on-asanko

Stainless steel and carbon steel engineer and manufacturer ZK International Group (NASDAQ: ZKIN) has regained compliance with N...

 top-4-materials-stocks-that-may-collapse-this-quarter

As of Dec. 26, 2023, four stocks in the materials sector could be flashing a real warning to investors who value momentum as a ...

 bmo-capital-maintains-market-perform-on-ingevity-lowers-price-target-to-43

BMO Capital analyst John McNulty maintains Ingevity (NYSE:NGVT) with a Market Perform and lowers the price target from $54 t...

 ingevity-announces-further-repositioning-of-its-performance-chemicals-business-including-the-closure-of-its-deridder-louisiana-facility-and-additional-company-wide-cost-reduction-actions-total-estimated-business-and-corporate-savings-of-65m-75m

Company taking next steps in executing strategy that focuses on higher margin and higher growth specialty products, diversifies...

 ingevity-q3-adj-eps-121-inline-sales-44600m-miss-46428m-estimate

Ingevity (NYSE:NGVT) reported quarterly earnings of $1.21 per share which met the analyst consensus estimate. This is a 42.11 p...

 earnings-scheduled-for-november-1-2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of...

 earnings-outlook-for-ingevity
Earnings Outlook For Ingevity
10/31/2023 15:00:52

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION